Skip to main content
Jafron Biomedical Co.,Ltd. logo

Jafron Biomedical Co.,Ltd. — Investor Relations & Filings

Ticker · 300529 ISIN · CNE100002995 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,842 across all filing types
Latest filing 2023-04-21 Declaration of Voting R…
Country CN China
Listing Shenzhen Stock Exchange 300529

About Jafron Biomedical Co.,Ltd.

https://www.jafron.com

Jafron Biomedical Co.,Ltd. specializes in the research, development, and manufacturing of biomaterials and equipment for blood purification. The company is a primary provider of hemoperfusion technology, focusing on the production of adsorbent cartridges designed to remove specific toxins and inflammatory mediators from the bloodstream. Its core product portfolio includes the HA series of hemoperfusion cartridges, which are applied in clinical settings for end-stage renal disease, acute poisoning, critical care, and liver failure. Beyond consumables, the company develops blood purification machines and integrated treatment systems. These solutions target clinical applications in nephrology, intensive care, and hepatology. By leveraging advanced resin adsorption technology, the company provides specialized extracorporeal blood treatment options aimed at improving patient outcomes in complex medical conditions.

Recent filings

Filing Released Lang Actions
2022年度股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a detailed announcement of the resolutions passed at the 2022 Annual General Meeting (AGM) of 健帆生物科技集团股份有限公司. It includes information about the meeting date, attendance, voting results on various proposals including the annual report, board reports, financial reports, profit distribution, remuneration, election of directors and supervisors, and other corporate governance matters. The document is not the annual report itself but the official announcement of the voting results and resolutions from the AGM. It contains detailed voting outcomes and legal opinions confirming the validity of the meeting and resolutions. Therefore, it fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2023-04-21 Chinese
关于董事会、监事会完成换届选举暨部分董事、监事、高级管理人任期届满离任的公告
Board/Management Information Classification · 100% confidence The document is an announcement from a company regarding the completion of the board of directors and supervisory board re-election, as well as the departure of some directors, supervisors, and senior management personnel due to term expiration. It details the composition of the new board, committees, and management appointments, along with biographies of the individuals involved. There is no financial data, earnings information, or audit content. The document is a formal announcement about changes in the company's board and senior management, fitting the category of Board/Management Information (MANG). The document length is sufficient and contains detailed information about management changes, not just a brief notice or report publication announcement.
2023-04-21 Chinese
第五届监事会第一次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of the resolution from the first meeting of the fifth Supervisory Board of the company. It details the election of the Supervisory Board chairman and confirms the meeting was held according to legal and company regulations. There is no financial data, no audit report, no earnings information, nor any mention of annual or interim reports. The document is an official announcement about board/management changes, specifically related to the Supervisory Board leadership. Therefore, it fits best under the category of Board/Management Information (MANG). The document length is short and it is not a report publication announcement or certification. Hence, the classification is MANG with high confidence.
2023-04-21 Chinese
关于2023年第一季度健帆转债转股情况的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the conversion of convertible bonds into shares for the first quarter of 2023 by 健帆生物科技集团股份有限公司. It details the bond issuance, conversion prices, conversion period, and the impact on the company's share capital structure. The document includes specific data on bond conversion quantities, share capital changes, and regulatory compliance references. It is not a full financial report, earnings release, or management discussion but a regulatory announcement about bond conversion and share capital changes. Given the content and nature, this fits best under Capital/Financing Update (CAP), as it updates on convertible bond conversions and related capital structure changes.
2023-04-03 Chinese
国浩律师（深圳）事务所关于公司实施员工持股计划的法律意见书
Capital/Financing Update Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the implementation of an employee stock ownership plan by a listed company. It contains detailed legal analysis, compliance checks against relevant laws and regulations, and procedural confirmations related to the employee stock ownership plan. It is not a financial report, earnings release, or regulatory filing per se, but a legal opinion supporting a corporate action. This type of document fits best under the category of Capital/Financing Update (CAP), as it relates to the company's financing and capital structure changes through an employee stock ownership plan. The document length and content confirm it is the full legal opinion, not just an announcement or certification. Therefore, the classification is CAP with high confidence.
2023-03-30 Chinese
监事会关于公司奋斗者一号员工持股计划相关事项的审核意见
Audit Report / Information Classification · 95% confidence The document is an audit opinion from the Supervisory Board regarding the company's employee stock ownership plan, referencing compliance with relevant laws and regulations, and confirming the legality and appropriateness of the plan. It is not a full annual report or financial statement but a specific audit or review related to governance and compliance of a particular corporate action. The document length is short (937 characters) and contains a formal opinion rather than financial data or report publication. Therefore, it fits best under Audit Report / Information (AR). Q1 2023
2023-03-30 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.